Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Benjamin O. Anderson MD, FACS Advisory Board

Annette Hasenburg Prof., Dr, med Advisory Board

See All Experts

featured

Published in Oncology

Journal Scan / Research · February 18, 2016

Cola Impacts Absorption of Erlotinib in NSCLC

Journal of Clinical Oncology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Journal of Clinical Oncology

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer

J. Clin. Oncol 2016 Feb 08;[EPub Ahead of Print], RW van Leeuwen, R Peric, KG Hussaarts, E Kienhuis, NS IJzerman, P de Bruijn, C van der Leest, H Codrington, JS Kloover, B van der Holt, JG Aerts, T van Gelder, RH Mathijssen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Cola Impacts Absorption of Erlotinib in NSCLC

Additional Info

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer

Further Reading

Final Note From the Oncology Editors

Invasive Disease–Free Survival Outcomes With SLNB vs Omission of Axillary Surgery in Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Surgery

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

Genomic Instability in Non–Breast or Ovarian Malignancies Among Individuals With Germline Pathogenic Variants in BRCA1/2

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Obecabtagene Autoleucel for Adults With B-Cell Acute Lymphoblastic Leukemia

De-Escalated Neoadjuvant Weekly Nab-Paclitaxel With Trastuzumab and Pertuzumab vs Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for HER2-Positive Early Breast Cancer

Blinatumomab in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia

Tremelimumab and Durvalumab as Neoadjuvant or Non-Operative Management Strategy for Microsatellite Instability–High Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Efficacy and Safety of Prostate Radiotherapy in Patients With De Novo Metastatic Castration-Sensitive Prostate Cancer

Recently Updated